Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

BACKGROUND: Atypical tumor response patterns during immune checkpoint inhibitor therapy pose a challenge to clinicians and investigators in immuno-oncology practice. This study evaluated tumor burden dynamics to identify imaging biomarkers for treatment response and overall survival (OS) in advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Peiyi, Zheng, Hong, Chen, Haiyang, Wei, Kaikai, Pan, Ximin, Xu, Qinmei, Wang, Yongchen, Tang, Changguan, Gevaert, Olivier, Meng, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605503/
https://www.ncbi.nlm.nih.gov/pubmed/34798858
http://dx.doi.org/10.1186/s12885-021-08944-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605503/
https://www.ncbi.nlm.nih.gov/pubmed/34798858
http://dx.doi.org/10.1186/s12885-021-08944-9

Ejemplares similares